Cracking the Code of Obstruction: Unmet Needs in oHCM
About this episode
This episode discusses the management of obstructive hypertrophic cardiomyopathy and the challenges in treatment options.
Faculty: Michael Nassif, MD, MSc This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
More episodes of CME
- Counseling Patients on Their Future with Biologics
- Safety in oHCM Therapy: How and When to Transition Treatment?
- Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
- Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Explore listener stats, chart rankings, contacts and more on the CME podcast page.